EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Mutational Landmarks in Anaplastic Thyroid Cancer: A Perspective of a New Treatment Strategy

Janice Pakkianathan iD, Celina R Yamauchi, Luiza Barseghyan, Joseph Cruz, Alfred A Simental, Salma Khan iD

Journal of Clinical Medicine · 23.04.2025 · 14 (9) · 2898

DOI: 10.3390/jcm14092898 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 23.04.2025. Verfasst von Janice Pakkianathan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, School of Medicine, Loma Linda University, Loma Linda, CA 92350, USA. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anaplastic thyroid carcinoma (ATC) is the rarest and most aggressive form of thyroid cancer, marked by a poor prognosis and resistance to conventional treatments. Like many malignancies, ATC has a complex genetic landscape, with numerous mutations driving tumor initiation, progression, and therapeutic resistance. However, recent advances in molecular research have expanded our understanding of these genetic alterations, paving the way for new targeted treatment strategies. Currently, therapies targeting specific genetic mutations, such as BRAF and MEK, show promise, but their effectiveness is limited to patients harboring these mutations. To explore broader therapeutic possibilities, we conducted a comprehensive literature review using the PubMed database and Google to identify studies on key genetic mutations in ATC. By leveraging these molecular insights, we aim to highlight potential therapeutic avenues that could enhance treatment options and improve patient outcomes.

Schlagwörter

Stichwörter der Autor:innen

BRAF-V600EMEKTERTanaplastic thyroid cancerp53targeted therapy

Autor:innen und Institutionen

  • Department of Biochemistry, School of Medicine, Loma Linda University, Loma Linda, CA 92350, USA.
  • Center for Health Disparities & Molecular Medicine, School of Medicine, Loma Linda University, Loma Linda, CA 92350, USA.
  • Department of Otolaryngology, School of Medicine, Loma Linda University, Loma Linda, CA 92350, USA.

ORCID-Profile: Janice Pakkianathan, Salma Khan

Zitieren

APA

Pakkianathan, J., Yamauchi, C. R., Barseghyan, L., Cruz, J., Simental, A. A., & Khan, S. (2025). Mutational Landmarks in Anaplastic Thyroid Cancer: A Perspective of a New Treatment Strategy. Journal of Clinical Medicine, 14(9), 2898. https://doi.org/10.3390/jcm14092898

Vancouver

Pakkianathan J, Yamauchi CR, Barseghyan L, Cruz J, Simental AA, Khan S. Mutational Landmarks in Anaplastic Thyroid Cancer: A Perspective of a New Treatment Strategy. Journal of Clinical Medicine. 2025;14(9):2898. doi:10.3390/jcm14092898

BibTeX
@article{Pakkianathan2025,
  author = {Pakkianathan, Janice and Yamauchi, Celina R and Barseghyan, Luiza and Cruz, Joseph and Simental, Alfred A and Khan, Salma},
  title = {Mutational Landmarks in Anaplastic Thyroid Cancer: A Perspective of a New Treatment Strategy},
  journal = {Journal of Clinical Medicine},
  year = {2025},
  volume = {14},
  number = {9},
  pages = {2898},
  doi = {10.3390/jcm14092898}
}
Kostenlos starten →